Suppliers and packagers for TIMOLOL

TIMOLOL

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Somerset	TIMOLOL	timolol	SOLUTION/DROPS;OPHTHALMIC	216654	ANDA	Somerset Therapeutics, LLC	70069-696-01	1 BOTTLE in 1 CARTON (70069-696-01) / 5 mL in 1 BOTTLE	2024-10-31
Somerset	TIMOLOL	timolol	SOLUTION/DROPS;OPHTHALMIC	216654	ANDA	Somerset Therapeutics, LLC	70069-697-01	1 BOTTLE in 1 CARTON (70069-697-01) / 10 mL in 1 BOTTLE	2024-10-31
Somerset	TIMOLOL	timolol	SOLUTION/DROPS;OPHTHALMIC	216654	ANDA	Somerset Therapeutics, LLC	70069-698-01	1 BOTTLE in 1 CARTON (70069-698-01) / 15 mL in 1 BOTTLE	2024-10-31

TimoLol Drug Suppliers and Manufacturing Sources: APIs, Formulations, and Contract Manufacturers

Last updated: May 24, 2026

Major timoIol suppliers span multiple IP and distribution channels. At a high level, procurement typically splits into (1) timoIol maleate and timoIol hemihydrate API sources, (2) finished-dose generic and branded timoIol products (ophthalmic, oral, topical), and (3) contract manufacturers that do fill-finish and packaging for sterile eye drops and solid oral dosage.

Who supplies the timoLol API (active pharmaceutical ingredient)

Core API suppliers for timoIol products are usually global generics and API manufacturers with capability for standard salt forms such as:

• TimoIol maleate
• TimoIol hemihydrate (depending on product lineage and regional practice)
• TimoIol base (less common as an intermediate, more common for specific synthetic routes)

How procurement typically maps in practice

• API route: API supplier supplies salt-form API aligned with pharmacopeia monographs for ocular and/or oral use.
• Finished dose: Finished product is sourced from branded holders, large generics, or contract manufacturers that specialize in ophthalmic sterile products.
• Regulatory: DMF-registered API sources in the relevant regions often dominate because they reduce qualification burden.

Which companies supply finished timoLol products (eye drops, gel, solution, tablets)

TimoIol is sold in multiple therapeutic and dosage forms, and supplier networks differ by form.

Ophthalmic timoLol (most common): solution, gel, and eye drops

Procurement targets tend to concentrate among:

• Large ophthalmic generics companies
• Specialty sterile fill-finish contractors
• Regional distributors that support local label requirements

Typical finished-dose categories

• TimoIol ophthalmic solution
• TimoIol ophthalmic gel-forming solution
• Preservative-free versus preserved multi-dose formats (supply availability and fill-finish constraints vary)

Topical and systemic timoLol (dermal/oral depending on market)

Where available, suppliers also split by dosage form:

• Oral timoIol (where marketed in a given country)
• Topical dermatologic formulations (market-specific)
• Combination products (timoIol with other actives) can shift supply to combination formulators and packaging lines.

What finished-dose suppliers dominate timoLol ophthalmic generics

Dominant suppliers for timoIol ophthalmic generics generally include global generics leaders and regionally scaled ophthalmic manufacturers, often with:

• Multiple strength SKUs (0.25%, 0.5% typical for ophthalmic markets)
• Multiple presentation formats (unit-dose or multi-dose)
• Bottle, dropper, and sterile manufacturing qualification

Supply-chain reality

• Sterile ocular manufacturing and packaging are constrained by cleanroom capacity and validation slots. The supplier base can be stable but tight during regulatory remediation cycles or site expansions.

How do timoLol suppliers differ by salt form and strength

Salt form is often the hidden procurement driver because it governs:

• API specification and impurity profile
• Formulation solubility and pH targets
• Stability behavior (especially for ophthalmic solutions)

Common formulation implications

• TimoIol maleate is widely used in ophthalmic formulations.
• Strength and excipient sets affect which API salt is easiest to support under an established manufacturing process.
• Preservative system choices (e.g., benzalkonium chloride in preserved formats) affect compatibility and container closure selection.

Which contract manufacturers support sterile ophthalmic fill-finish for timoLol

Contract manufacturing typically includes:

• Sterile compounding and filling
• Container closure systems compatible with drop mechanics and preservative regimes
• Sterilization approach validation (or aseptic processing controls, depending on method)
• Ocular-grade packaging and labeling lines

Supplier selection criteria buyers use

• DMF/ASMF compatibility for the API used
• Prior ophthalmic line history (sterile drop products)
• Ability to support preservative-free unit-dose if required
• Release testing capacity for ocular sterility, particulates, and viscosity targets

What patent/IP holders influence supplier access to timoLol

Supplier access is usually less constrained than with novel biologics, because timoIol is an established small-molecule. Still, practical constraints come from:

• Process and formulation patents for specific dosage forms (especially gel-forming systems and preservative-free presentations)
• Data exclusivity and regulatory history that can affect abbreviated application referencing
• Trademark and branded packaging logistics

Procurement impact

• Generic manufacturing is generally feasible, but specific presentations (unit-dose preservative-free, gel-forming) may be controlled by more recent formulation or device-related IP.

Orange Book and FDA status: why it changes the supplier landscape

For U.S. procurement, the key operational point is that FDA-listed products and their listed patents determine whether ANDA entrants face litigation or exclusivity barriers.

Typical buyer behavior

• Map the Orange Book listings for the exact NDC and dosage form.
• Identify whether the product is served through:
  • Authorized generics
  • Filed generics with paragraph IV certifications
  • Licenses or settlements that define launch timing.

What generic entry risks exist for timoLol

For an established molecule like timoIol, generic entry risks are usually tied to:

• Ocular formulation-specific IP (gel formulations, preservative-free)
• Device/container closure IP (dropper and container system)
• Competitive dynamics in local tender markets and pharmacy channels
• Ongoing FDA inspections and manufacturing deviations that constrain supply

How to structure a supplier qualification plan for timoLol

Procurement teams typically run qualifications in parallel across API and finished dose.

API qualification checkpoints

• Pharmacopeia compliance for the intended salt form
• Impurity and residual solvent profiles aligned to the formulation target
• DMF/ASMF alignment with the chosen finished-dose regulatory strategy

Finished-dose qualification checkpoints

• Sterility assurance and container closure integrity
• Stability data under the target storage conditions
• Drop size distribution and delivery accuracy testing (for ophthalmic)

Competitive landscape: what buyers typically see

Large multinational generics houses and ophthalmic specialists dominate finished timoIol supply because they can:

• Maintain multiple strengths and presentations
• Absorb batch testing costs and sterile fill-finish lead times
• Support tender requirements and national account replenishment

Contract manufacturers supply overflow capacity and niche formats where the regulatory file is already built by a partner.

Key data pack for procurement due diligence (what to request)

• COA for each batch, including impurities and residual solvents (API)
• Sterility assurance package for sterile ocular lots (finished dose)
• Stability protocol and latest stability results
• Extractables/leachables summary by container closure (finished dose)
• Regulatory status: NDC mapping, labeling, and market authorization proof

Key Takeaways

• TimoIol supply splits into API sources (commonly timoIol maleate/hemihydrate, depending on product) and finished-dose manufacturers for ophthalmic sterile products.
• Ophthalmic formulations concentrate supplier capability in sterile fill-finish and ocular packaging capacity.
• Procurement risk is driven less by molecule novelty and more by dosage-form-specific formulation IP, container closure requirements, and FDA listing-linked competition dynamics.
• A qualification plan should cover API salt form specs, sterile ocular release testing, stability alignment, and container closure compatibility.

FAQs

1) Are timoLol maleate and timoLol hemihydrate interchangeable for sourcing?
No. They differ in physicochemical properties and formulation behavior, so suppliers must match the target salt form used in the marketed product and regulatory file.

2) What dosage forms have the highest supplier constraints for timoLol?
Preservative-free unit-dose and gel-forming ophthalmic formats usually face tighter sterile fill-finish and packaging constraints.

3) How does the Orange Book listing affect which timoLol generic suppliers can launch?
Orange Book-listed patents tied to the exact NDC and dosage form drive ANDA paragraph IV risk and settlement-based launch timing.

4) Can a contract manufacturer supply both API and finished timoLol?
Some manufacturers integrate API and sterile fill-finish, but many buyers source API from one qualified supplier and finished dose from a separate sterile contractor with ocular experience.

5) What documents matter most when qualifying an API supplier for timoLol?
DMF/ASMF alignment, pharmacopeia compliance, impurity profile, residual solvent controls, and batch COA traceability for the intended salt form.

References

1. U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Accessed via FDA Orange Book database).
2. U.S. Food and Drug Administration. Drug Master Files (DMF) Information.
3. International Conference on Harmonisation (ICH). ICH Q3A/Q3B Impurities guidelines (impurity control frameworks relevant to API qualification).